Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042172 · ClinicalTrials.gov registry record · Phase 4
Treatment for Early Memory Loss
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00042172 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 40 participants.
The verdict
NCT00042172, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.
Interventions
- DRUG Donepezil
- DRUG Ginkgo Biloba Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042172
The ClinicalTrials.gov registry entry for NCT00042172 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donepezil is the first listed.
NCT00042172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042172 about?
NCT00042172 is a clinical study titled "Treatment for Early Memory Loss". The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.
What is the current status of trial NCT00042172?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2002-06. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00042172?
The interventions under investigation include: Donepezil (DRUG), Ginkgo Biloba Extract (DRUG).
Who is sponsoring clinical trial NCT00042172?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.